Axogen, Inc. AXGN
50.64 USD +0.62 (+1.24%)
At closeNov 9, 2026, 5:41 PM EST
50.64 0.00 0.00%
After hours · Nov 9, 5:41 PM ET
49.48 Day range 51.48
23.00 52-week range 52.91
- YTD
- +54.72%
- 1 year
- +114.85%
News
globenewswire.com Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of…
zacks.com GMED vs. AXGN: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for…
benzinga.com Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $60 Canaccord Genuity analyst Caitlin Roberts maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $55 to $60.
benzinga.com Leerink Partners Maintains Outperform on Axogen, Raises Price Target to $56 Leerink Partners analyst Mike Kratky maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $52 to $56.
benzinga.com Barclays Maintains Overweight on Axogen, Raises Price Target to $60 Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $50 to $60.
benzinga.com Truist Securities Maintains Buy on Axogen, Raises Price Target to $60 Truist Securities analyst Ravi Misra maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $53 to $60.
benzinga.com Wells Fargo Maintains Overweight on Axogen, Raises Price Target to $56 Wells Fargo analyst Larry Biegelsen maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $48 to $56.
benzinga.com Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target was cut and its rating downgraded.
benzinga.com HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $56 HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $53 to $56.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
benzinga.com Axogen Q3 2026 Earnings Call Transcript Axogen (NASDAQ:AXGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…- benzinga.com Axogen Q3 Adj. EPS $0.21 Beats $0.14 Estimate, Sales $75.834M Beat $73.199M Estimate Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.14 by 50 percent. This is a 75 percent increase over earnings of $0.12 per share…
- benzinga.com Barclays Maintains Overweight on Axogen, Lowers Price Target to $50 Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and lowers the price target from $55 to $50.
benzinga.com This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating.
benzinga.com B of A Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $52 B of A Securities analyst Travis Steed initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target of $52.- benzinga.com Truist Securities Maintains Buy on Axogen, Lowers Price Target to $53 Truist Securities analyst Ravi Misra maintains Axogen (NASDAQ:AXGN) with a Buy and lowers the price target from $60 to $53.
benzinga.com AMD To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.- benzinga.com Raymond James Maintains Outperform on Axogen, Raises Price Target to $53 Raymond James analyst Jayson Bedford maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $48 to $53.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.- benzinga.com Axogen Prices $208.7M Underwritten Public Offering Of 4.91M Shares At $42.50 Per Share Axogen, Inc. ("Axogen" or the "Company") (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the
- benzinga.com Axogen To Acquire NerveTape Maker BioCircuit Technologies For $200M In Cash; Sees Deal As Accretive To FY27 Gross And Adjusted EBITDA Margins At closing, $1.0 million of the estimated merger consideration will be withheld pending determination of the post-closing purchase price adjustment. The transaction is expected to close in the fourth…
- benzinga.com Truist Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $60 Truist Securities analyst Ravi Misra initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target of $60.
- benzinga.com Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $55 Canaccord Genuity analyst Caitlin Roberts maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $50 to $55.
- benzinga.com Citizens Maintains Market Outperform on Axogen, Raises Price Target to $55 Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target from $50 to $55.
- benzinga.com HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $53 HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $50 to $53.
- benzinga.com Axogen Participates In Series A Funding Round For Trace Biosciences With Additional Investors Expected To Join; Terms Not Disclosed Nerve Trace is a near-infrared fluorescence imaging technology designed to provide direct, real-time visualization of nerves during surgery, including nerves that are otherwise obscured from view by…
- benzinga.com Axogen Q2 Adj. EPS $0.12 Misses $0.13 Estimate, Sales $69.731M Beat $67.098M Estimate Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.13 by 7.69 percent. This is unchanged from the same period last year. The company…
- benzinga.com Citizens Maintains Market Outperform on Axogen, Raises Price Target to $50 Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target from $42 to $50.
benzinga.com Wells Fargo Maintains Overweight on Axogen, Raises Price Target to $48 Wells Fargo analyst Larry Biegelsen maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $40 to $48.- benzinga.com HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $50 HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $39 to $50.
benzinga.com Full Transcript: Axogen Q1 2026 Earnings Call 
benzinga.com CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Earnings Scheduled For April 28, 2026 - benzinga.com Axogen FY2026 Revenue Expected To Be At Least $270.000M vs $266.219M Est Axogen (NASDAQ: AXGN) FY2026 Revenue expected to be at least $270.000M vs $266.219M EstAxogen (NASDAQ:AXGN) FY2026 Revenue expected to be at least $270.000M vs $266.219M Est
- benzinga.com Axogen Q1 Adj. EPS $0.07, Inline, Sales $61.457M Beat $57.725M Estimate Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 450 percent increase over losses of $(0.02) per share from the same period last…
- benzinga.com Lake Street Maintains Buy on Axogen, Raises Price Target to $50 Lake Street analyst Frank Takkinen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $40 to $50.
- benzinga.com Citizens Maintains Market Outperform on Axogen, Raises Price Target to $42 Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target from $34 to $42.
- benzinga.com CORRECTION: Axogen Sees FY2026 Revenue Of More Than $265.700M vs $259.499M Est 2026 Financial GuidanceWe expect 2026 revenue growth to be at least 18%, or $265.7 million, for the full-year and gross margin to be in the range of 74% to 76%. Additionally, we expect to be free…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Axogen Q4 Earnings Summary & Key Takeaways - benzinga.com Axogen Q4 Adj. EPS $0.07 Misses $0.08 Estimate, Sales $59.904M Beat $58.870M Estimate Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.08 by 12.5 percent. This is unchanged from the same period last year. The company…
- benzinga.com Earnings Scheduled For February 24, 2026
benzinga.com Axogen Earnings Preview 
benzinga.com Beyond The Numbers: 6 Analysts Discuss Axogen Stock 
benzinga.com This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday